DK0775103T3 - Retinsyre-X-receptorligander - Google Patents

Retinsyre-X-receptorligander

Info

Publication number: DK0775103T3
Authority: DK; Denmark
Prior art keywords: pct; retinoic acid; receptor ligands; sec; date
Prior art date: 1994-08-10

Application number

DK95930430T

Other languages

Danish (da)

English (en)

Inventor

Michael Klaus

Michael Rosenberger

Allen John Lovey

Peter Mohr

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-08-10

Filing date

1995-07-29

Publication date

1999-11-15

1995-07-29 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

1999-11-15 Application granted granted Critical

1999-11-15 Publication of DK0775103T3 publication Critical patent/DK0775103T3/da

Links

239000003446 ligand Substances 0.000 title 1
230000001028 anti-proliverative effect Effects 0.000 abstract 1
230000000771 oncological effect Effects 0.000 abstract 1
150000004492 retinoid derivatives Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
- C07C69/533—Monocarboxylic acid esters having only one carbon-to-carbon double bond
- C07C69/56—Crotonic acid esters; Vinyl acetic acid esters
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4056—Esters of arylalkanephosphonic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/27—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation
- C07C45/29—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation of hydroxy groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/27—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation
- C07C45/29—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation of hydroxy groups
- C07C45/298—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation of hydroxy groups with manganese derivatives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/63—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by introduction of halogen; by substitution of halogen atoms by other halogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C47/00—Compounds having —CHO groups
- C07C47/20—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms
- C07C47/24—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms containing halogen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C47/00—Compounds having —CHO groups
- C07C47/20—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms
- C07C47/277—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms containing ether groups, groups, groups, or groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/46—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid
- C07C57/50—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid containing condensed ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Dermatology (AREA)
Hematology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Obesity (AREA)
Oncology (AREA)
Diabetes (AREA)
Nutrition Science (AREA)
Epidemiology (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Steroid Compounds (AREA)
Paints Or Removers (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

DK95930430T 1994-08-10 1995-07-29 Retinsyre-X-receptorligander DK0775103T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP94112461		1994-08-10
EP95110460		1995-07-05
PCT/EP1995/003021 WO1996005165A1 (fr)	1994-08-10	1995-07-29	Ligands des recepteurs x de l'acide retinoique

Publications (1)

Publication Number	Publication Date
DK0775103T3 true DK0775103T3 (da)	1999-11-15

Family

ID=26135772

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK95930430T DK0775103T3 (da)	1994-08-10	1995-07-29	Retinsyre-X-receptorligander

Country Status (24)

Country	Link
US (1)	US5801253A (fr)
EP (1)	EP0775103B1 (fr)
JP (1)	JP2848964B2 (fr)
KR (1)	KR100363545B1 (fr)
CN (1)	CN1091092C (fr)
AT (1)	ATE181052T1 (fr)
AU (1)	AU696501B2 (fr)
BR (1)	BR9508985A (fr)
CA (1)	CA2196197C (fr)
CY (1)	CY2170B1 (fr)
CZ (1)	CZ288526B6 (fr)
DE (1)	DE69510203T2 (fr)
DK (1)	DK0775103T3 (fr)
ES (1)	ES2133798T3 (fr)
FI (1)	FI112357B (fr)
GR (1)	GR3031154T3 (fr)
HU (1)	HU218268B (fr)
MX (1)	MX9700778A (fr)
NO (1)	NO307702B1 (fr)
NZ (1)	NZ292121A (fr)
PL (1)	PL180048B1 (fr)
RU (1)	RU2146241C1 (fr)
TR (1)	TR199500976A2 (fr)
WO (1)	WO1996005165A1 (fr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5466861A (en) *	1992-11-25	1995-11-14	Sri International	Bridged bicyclic aromatic compounds and their use in modulating gene expression of retinoid receptors
IL116259A (en) *	1994-12-19	2000-07-16	American Cyanamid Co	Analogs of 9-cis retinoic acid and their use
US5968908A (en) *	1994-12-19	1999-10-19	American Cyanamid Company	Restricted 9-cis retinoids
US7115728B1 (en)	1995-01-30	2006-10-03	Ligand Pharmaceutical Incorporated	Human peroxisome proliferator activated receptor γ
US5675033A (en) *	1995-06-06	1997-10-07	Allergan	2,4-pentadienoic acid derivatives having retinoid-like biological activity
US6942980B1 (en)	1995-09-01	2005-09-13	Allergan, Inc.	Methods of identifying compounds having nuclear receptor negative hormone and/or antagonist activities
US6028052A (en)	1995-09-18	2000-02-22	Ligand Pharmaceuticals Incorporated	Treating NIDDM with RXR agonists
CA2233888A1 (fr)	1995-10-06	1997-04-10	Ligand Pharmaceuticals Incorporated	Modulateurs rxr selectifs pour les dimeres et leurs methodes d'utilisation
FR2746101B1 (fr) *	1996-03-14	1998-04-30		Composes bicycliques-aromatiques
US5741896A (en)	1996-06-21	1998-04-21	Allergan	O- or S- substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
JP2000511558A (ja) *	1996-06-21	2000-09-05	アラーガン・セイルズ・インコーポレイテッド	レチノイドおよび／またはレチノイド拮抗剤様生物学的活性を有する置換テトラヒドロナフタレンおよびジヒドロナフタレン誘導体
EP1410799B1 (fr)	1996-12-11	2010-03-31	Dana-Farber Cancer Institute, Inc.	Méthodes et composés pharmaceutiques pour inhiber la croissance des tumeurs
US5728846A (en)	1996-12-12	1998-03-17	Allergan	Benzo 1,2-g!-chrom-3-ene and benzo 1,2-g!-thiochrom-3-ene derivatives
US5919970A (en) *	1997-04-24	1999-07-06	Allergan Sales, Inc.	Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
US7098025B1 (en)	1997-07-25	2006-08-29	Ligand Pharmaceuticals Incorporated	Human peroxisome proliferator activated receptor gamma (pparγ) gene regulatory sequences and uses therefor
KR100440836B1 (ko) *	1997-11-12	2004-07-19	에프. 호프만-라 로슈 아게	레티노이드 길항제를 이용한 제2형 ｔ-보조세포 중재 면역질환의 치료
US6242196B1 (en)	1997-12-11	2001-06-05	Dana-Farber Cancer Institute	Methods and pharmaceutical compositions for inhibiting tumor cell growth
CA2334545A1 (fr) *	1998-06-12	1999-12-16	Ligand Pharmaceuticals Incorporated	Traitement du cancer du sein resistant aux anti-oestrogenes avec des modulateurs de rxr
US6048873A (en) *	1998-10-01	2000-04-11	Allergan Sales, Inc.	Tetrahdroquinolin-2-one 6 or 7-yl, tetrahdroquinilin-2-thione 6 or 7-yl pentadienoic acid and related derivatives having retinoid-like biological activity
US6147224A (en) *	1998-10-01	2000-11-14	Allergan Sales, Inc.	2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors
US6403638B1 (en) *	1998-10-01	2002-06-11	Allergan Sales, Inc.	2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors
US6326397B1 (en)	1998-11-10	2001-12-04	Hoffman-La Roche Inc.	Retinoid antagonists and use thereof
EP1212322A2 (fr)	1999-08-27	2002-06-12	Ligand Pharmaceuticals Incorporated	Composes de 6-trifluoromethyl-9-pyrido[3,2-g]quinoline 8-substitues utilises comme modulateurs de recepteurs androgenes
US6566372B1 (en)	1999-08-27	2003-05-20	Ligand Pharmaceuticals Incorporated	Bicyclic androgen and progesterone receptor modulator compounds and methods
TR200200507T2 (tr)	1999-08-27	2002-10-21	Ligand Pharmaceuticals Inc	Androjen reseptörü modülatör bileşikleri ve metotları
AU7586600A (en)	1999-09-14	2001-04-17	Ligand Pharmaceuticals Incorporated	Rxr modulators with improved pharmacologic profile
PT1741446E (pt)	2000-01-21	2008-05-09	Novartis Pharma Ag	Combinações incluindo inibidores da dipeptidilpeptidase-iv e agentes anti-diabéticos
US6369225B1 (en)	2000-08-29	2002-04-09	Allergan Sales, Inc.	Compounds having activity as inhibitors of cytochrome P450RAI
US6313107B1 (en)	2000-08-29	2001-11-06	Allergan Sales, Inc.	Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI
US6380256B1 (en)	2000-08-29	2002-04-30	Allergan Sales, Inc.	Compounds having activity as inhibitors of cytochrome P450RAI
DE60136477D1 (de) *	2000-10-02	2008-12-18	Hoffmann La Roche	Retinoide zur behandlung von emphysem
EP1373240B1 (fr) *	2001-03-14	2005-06-15	Eli Lilly And Company	Modulateurs des recepteurs x de retinoides
US6720423B2 (en)	2002-04-30	2004-04-13	Allergan, Inc.	Dihydrobenzofuran and dihydrobenzothiophene 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors
WO2004048390A1 (fr) *	2002-11-25	2004-06-10	Amedis Pharmaceuticals Ltd.	Composes de silicium
US6759547B1 (en)	2003-01-14	2004-07-06	Allergan, Inc.	5,6,7,8-tetrahydronaphthalen-2-yl 2,6-difluoroheptatrienoic acid derivatives having serum glucose reducing activity
US7019034B2 (en) *	2003-01-28	2006-03-28	Allergan, Inc.	Compositions and methods for reducing serum glucose and triglyceride levels in diabetic mammals
US6759546B1 (en)	2003-02-04	2004-07-06	Allergan, Inc.	3,5-di-iso-propyl-heptatrienoic acid derivatives having serum glucose reducing activity
US6884820B2 (en) *	2003-04-03	2005-04-26	Allergan, Inc.	5,6,7,8-tetrahydronaphthalen-2-yl-7-fluoroalkyl-heptatrienoic acid derivatives having serum glucose reducing activity
US6734193B1 (en)	2003-06-03	2004-05-11	Allergan, Inc.	(1,2,3,4-tetrahydroquinolin-8-yl)-heptatrienoic acid derivatives having serum glucose reducing activity
AU2004263156B2 (en) *	2003-08-07	2009-02-26	Allergan, Inc.	Method for treating cachexia with retinoid ligands
US6887896B1 (en)	2003-10-29	2005-05-03	Allergan, Inc.	7-[(7-Alkoxy)-chrom-3-en-6-yl]-heptatrienoic acid and 7-[(3-alkoxy)-5,6-dihydronaphthalen-2-yl]-heptatrienoic acid derivatives having serum glucose reducing activity
US9050310B2 (en)	2004-06-25	2015-06-09	Minas Theodore Coroneo	Treatment of ocular lesions
WO2007048510A1 (fr) *	2005-10-25	2007-05-03	Werner Bollag	Agonistes et antagonistes rxr, seuls ou en conjonction avec des ligands ppar, dans le traitement des maladies métaboliques et cardiovasculaires
US20070185055A1 (en) *	2006-02-06	2007-08-09	Guang Liang Jiang	Method for treating cachexia with retinoid ligands
US20090209601A1 (en) *	2008-02-15	2009-08-20	Wyeth	Use of rxr agonists for the treatment of osteoarthritis
JP5877466B2 (ja) *	2012-02-29	2016-03-08	国立大学法人岡山大学	テルペノイド由来レチノイド化合物
WO2015059632A1 (fr)	2013-10-23	2015-04-30	Acadia Pharmaceuticals Inc.	Traitement d'une maladie ou un trouble neurodégénératif
US11045441B2 (en)	2015-10-13	2021-06-29	Wisconsin Alumni Research Foundation	Use of retinoic acid and analogs thereof to treat central neural apneas
EP3687482A1 (fr) *	2017-09-28	2020-08-05	Johnson & Johnson Consumer Inc.	Compositions cosmétiques et procédé de traitement de la peau
CN113302206A (zh)	2018-11-26	2021-08-24	戴纳立制药公司	治疗脂质代谢失调的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH651007A5 (de) *	1982-06-24	1985-08-30	Hoffmann La Roche	Polyenverbindungen.
EP0170105B1 (fr) *	1984-07-07	1990-10-17	Koichi Prof. Dr. Shudo	Dérivés de l'acide benzoique
FR2613360B1 (fr) *	1987-04-03	1989-06-09	Oreal	Nouveaux derives aromatiques d'acide butyrique, leur procede de preparation et leur utilisation en medecine humaine et veterinaire ainsi qu'en cosmetique
DE10199033I2 (de) *	1992-04-22	2003-01-09	Ligand Parmaceuticals Inc	Retinoid-x Rezeptor selektive Verbindungen
US5466861A (en) *	1992-11-25	1995-11-14	Sri International	Bridged bicyclic aromatic compounds and their use in modulating gene expression of retinoid receptors
JPH08511027A (ja) *	1993-01-11	1996-11-19	リガンド・ファーマシューティカルズ・インコーポレーテッド	レチノイドｘレセプターに対して選択的な活性を有する化合物、およびレチノイドｘレセプターによって媒体されたプロセスの調節手段
US5344959A (en) *	1993-05-18	1994-09-06	Allergan, Inc.	Tetrahydronaphthyl and cyclopropyl substituted 1,3-butadienes having retinoid-like activity

1995
- 1995-07-29 ES ES95930430T patent/ES2133798T3/es not_active Expired - Lifetime
- 1995-07-29 HU HU9700356A patent/HU218268B/hu not_active IP Right Cessation
- 1995-07-29 BR BR9508985A patent/BR9508985A/pt not_active IP Right Cessation
- 1995-07-29 EP EP95930430A patent/EP0775103B1/fr not_active Expired - Lifetime
- 1995-07-29 NZ NZ292121A patent/NZ292121A/xx unknown
- 1995-07-29 CZ CZ1997382A patent/CZ288526B6/cs not_active IP Right Cessation
- 1995-07-29 JP JP8506962A patent/JP2848964B2/ja not_active Expired - Fee Related
- 1995-07-29 MX MX9700778A patent/MX9700778A/es not_active IP Right Cessation
- 1995-07-29 CN CN95194064A patent/CN1091092C/zh not_active Expired - Fee Related
- 1995-07-29 US US08/776,087 patent/US5801253A/en not_active Expired - Fee Related
- 1995-07-29 WO PCT/EP1995/003021 patent/WO1996005165A1/fr not_active Ceased
- 1995-07-29 DE DE69510203T patent/DE69510203T2/de not_active Expired - Fee Related
- 1995-07-29 PL PL95318557A patent/PL180048B1/pl not_active IP Right Cessation
- 1995-07-29 AT AT95930430T patent/ATE181052T1/de not_active IP Right Cessation
- 1995-07-29 AU AU33821/95A patent/AU696501B2/en not_active Ceased
- 1995-07-29 CA CA002196197A patent/CA2196197C/fr not_active Expired - Fee Related
- 1995-07-29 RU RU97106022A patent/RU2146241C1/ru not_active IP Right Cessation
- 1995-07-29 DK DK95930430T patent/DK0775103T3/da active
- 1995-07-29 KR KR1019970700814A patent/KR100363545B1/ko not_active Expired - Fee Related
- 1995-08-08 TR TR95/00976A patent/TR199500976A2/xx unknown
1997
- 1997-02-07 FI FI970547A patent/FI112357B/fi not_active IP Right Cessation
- 1997-02-07 NO NO970580A patent/NO307702B1/no unknown
1999
- 1999-09-03 GR GR990402243T patent/GR3031154T3/el unknown
2000
- 2000-05-08 CY CY0000016A patent/CY2170B1/xx unknown

Also Published As

Publication number	Publication date
FI112357B (fi)	2003-11-28
JP2848964B2 (ja)	1999-01-20
PL180048B1 (en)	2000-12-29
NZ292121A (en)	1998-10-28
JPH09512830A (ja)	1997-12-22
FI970547A0 (fi)	1997-02-07
PL318557A1 (en)	1997-06-23
CN1091092C (zh)	2002-09-18
AU3382195A (en)	1996-03-07
KR970704663A (ko)	1997-09-06
HUT76839A (en)	1997-11-28
CN1152302A (zh)	1997-06-18
GR3031154T3 (en)	1999-12-31
NO970580L (no)	1997-02-07
CA2196197C (fr)	2007-04-17
WO1996005165A1 (fr)	1996-02-22
FI970547L (fi)	1997-02-07
BR9508985A (pt)	1998-01-06
EP0775103B1 (fr)	1999-06-09
NO307702B1 (no)	2000-05-15
CA2196197A1 (fr)	1996-02-22
HU218268B (hu)	2000-06-28
AU696501B2 (en)	1998-09-10
DE69510203D1 (de)	1999-07-15
KR100363545B1 (ko)	2003-02-19
TR199500976A2 (tr)	1996-06-21
NO970580D0 (no)	1997-02-07
CY2170B1 (en)	2002-08-23
EP0775103A1 (fr)	1997-05-28
DE69510203T2 (de)	1999-12-23
ATE181052T1 (de)	1999-06-15
RU2146241C1 (ru)	2000-03-10
CZ38297A3 (en)	1997-06-11
US5801253A (en)	1998-09-01
ES2133798T3 (es)	1999-09-16
MX9700778A (es)	1997-05-31
CZ288526B6 (cs)	2001-07-11

Publication	Publication Date	Title
DK0775103T3 (da)	1999-11-15	Retinsyre-X-receptorligander
ATE167476T1 (de)	1998-07-15	Substituierte 2-phenyl-3-methocypropensäurenester als fungizide mittel.
DE69530701D1 (de)	2003-06-12	Verwendung von 2,7,8-Trimethyl-2-( beta-Carboxyethyl )-6-Hydroxy-Chroman (LLU-alpha)
BG45701A3 (bg)	1989-07-14	Метод за получаване на алфа-хетероциклично заместени толунитрили
DE59009034D1 (de)	1995-06-08	Desodorierende kosmetische mittel.
ATE221887T1 (de)	2002-08-15	Substituierte 1,2,4-triazolo(3,4,-a)phthalazin- derivate als gaba-alpha 5-liganden
ATE192731T1 (de)	2000-05-15	Retinoid trienverbindungen und verfahren
DE59508391D1 (de)	2000-06-29	Metallkomplexe mit geladenem linker
RU95101375A (ru)	1996-11-20	Производные n-(3-аминопропил)-n-фенил-5,6,7,8-тетрагидронафталин-2-карбоксамида, их получение и применение в терапии
ATE242236T1 (de)	2003-06-15	N-substituierte 3-azabicyclo(3.2.0)heptan- derivate als neuroleptika
ES2174113T3 (es)	2002-11-01	Nuevos derivados de ((3-alcoxi-fenoxi)-etil)-dialquilamina y su utilizacion como anestesicos locales.
DE69513837D1 (de)	2000-01-13	Cyklopeptolide
DE19780509D2 (de)	1999-08-05	Komplexe Zubereitungen gekennzeichnet durch ein Gehalt an Betain
ES2141978T3 (es)	2000-04-01	Retinoides triciclicos, metodos para su produccion y uso.
CA1273582C (fr)	1990-09-04	Compose de pantethine pour l'ondulation permanente des cheveux
ATE128649T1 (de)	1995-10-15	Leimwerk mit zugeordnetem vorschmelzer für einen klebebinder.
ATE397011T1 (de)	2008-06-15	Verwendung von inhibitoren von asparaginyl- endopeptidase aus säugetieren zur modulierung des immunsystemen
ATE175971T1 (de)	1999-02-15	Wasserlösliche retinoide
YU15496A (sh)	1999-03-04	Postupak za dobijanje inhibitora hiv proteaze iz (2s)-4-pikolil-2-piperazin-t-butilkarboksiamida
ATE136884T1 (de)	1996-05-15	Neue 2-mercaptomethylen-tetrahydronaphthalin- und -indan-2-carboxamide als enkephalinaseinhibitoren
TR199701011A2 (xx)	1998-04-21	1-karba-(detia)-sefalosforin t�revleri.
PT98335A (pt)	1992-06-30	Processo de preparacao de sulfinilpristinamicina iib
KR960033288U (ko)	1996-11-19	2초에 착용하는 향기 넥타이
AR006752A1 (es)	1999-09-29	Formulaciones topicas que comprenden un vehículo topico y 3'-(l-ascorbil-2-fosforil)-colesterol ó 3'-(l-ascorbil-3- fosforil)-colesterol.
GR1001393B (el)	1993-10-29	Παράγωγα ιμιδαζο[2,1-Β] 3] βενζαζεπίνης, συν?έσεις και μέ?οδος χρήσεως.